에서 실시간으로 운영 중이에요! 자세히 알아보기

Precigen

PGEN

시가총액 US$22.8억

6.38 USD

-0.82

11.39%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

6.46

+0.08

1.25%

1일

-11.39%

5일

-17.89%

1개월

-14.25%

3개월

28.89%

6개월

61.52%

연초 이후

49.07%

1년

82.81%

5년

35.17%

10년

-75.08%

소개: Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

직원 수: 47

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 66.7%

중립 33.3%

부정적 0%

Zacks Investment Research

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Zacks Investment Research

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

Zacks Investment Research

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Zacks Investment Research

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

Zacks Investment Research

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Zacks Investment Research

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

Zacks Investment Research

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Zacks Investment Research

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.